转录因子E2F-4的表达与乳腺癌分级、分期及预后的关系

Expression of transcription factor E2F-4 in breast cancer and its relationship with histological grading, clinical staging and prognosis

目的:探讨乳腺癌中转录因子E2F-4的表达与临床分期、病理组织学分级及其预后等参数的关系。方法:采用免疫组化学的方法检测乳腺癌组织中E2F-4的表达,半定量分析E2F-4的表达与肿瘤分期、分级、术后生存时间等临床病理学参数的关系;以正常乳腺组织作为对照。结果:正常乳腺小叶及导管上皮细胞之E2F-4表达呈阴性;65例乳腺癌中33例(50.8%)呈E2F-4高表达;E2F-4高表达与乳腺癌的病理学分级、类型、临床分期以及术后生存时间有关(P<0.05)。结论:E2F-4作为肿瘤的相关基因,参与了乳腺癌的发生、发展。E2F-4的高表达可能是评判乳腺癌恶性程度、转移、复发及预后的较好指标。

Objective To investigate the relationship between the expression of transcription factor E2F-4 in breast cancer and its clinico-pathological parameters including histological grading, clinical staging and prognosis. Methods The expression of E2F-4 protein in breast cancer was detected by immunohistochemical staining. The relationship between E2F4 expression and clinico-pathological parameters. Normal mammary tissues were used as controls. Results Absence of E2F-4 expression was found in normal mammary tissues. Overexpression of E2F-4 protein was found in 50.8% of the breast cancer cases （33/65）. Over-expression of transcription factor E2F-4 in breast cancer was closely related with the histological grading, clinical staging and poor prognosis（P〈0.05）. Conclusions E2F-4 may be involved in the carcinogenesis and staging of breast cancer. The over-expression of E2F-4 might be used as a new marker to predict the metastatic potential and outcome of breast cancer.